Table 1 Baseline patient characteristics
|  |  | Anti-CTLA-4 | Anti-PD-1 | Combination | Fisher’s test |
|---|---|---|---|---|---|
|  | (n = 37) | (n = 27) | (n = 11) | p value | |
| Â | No. (%) | No. (%) | No. (%) | ||
Gender | Â Female | 12 (32) | 11 (41) | 4 (36) | 0.848 |
| Â | Â Male | 25 (68) | 16 (59) | 7 (64) | Â |
Age at treatment initiation | Â Mean (SD) | 66.2 (13) | 69.9 (14) | 59.9 (13) | 1 |
| Â | Â Median | 67.4 | 71 | 61.1 | Â |
ECOG PS (pretreatment) | Â 0 | 28 (76) | 19 (70) | 7 (64) | 0.736 |
|  |  > 1 | 9 (24) | 8 (30) | 4 (36) |  |
LDH (pretreatment) | Â Normal | 31 (91) | 19 (70) | 9 (82) | 0.114 |
| Â | Â Elevated | 0 (9) | 8 (30) | 2 (18) | Â |
| Â | Â Unknown | 3 | 0 | 0 | Â |
Response to treatment | Â POD | 22 (59) | 10 (37) | 4 (36) | 0.01 |
| Â | Â SD | 10 (27) | 5 (19) | 1 (9) | Â |
| Â | Â PR | 5 (14) | 8 (30) | 2 (18) | Â |
| Â | Â CR | 0 | 2 (7) | 4 (36) | Â |
| Â | Â UNC | 0 | 2 (7) | 0 | Â |
Toxicity | Â None | 8 (22) | 4 (15) | 0 | Â |
| Â | Â Mild | 20 (54) | 15 (55) | 4 (36) | 0.16 |
| Â | Â Severe | 9 (24) | 8 (30) | 7 (64) | Â |
GI toxicity | Â Mild | 9 (23.1) | 12 (42.9) | 3 (27.3) | 0.08 |
| Â | Â Severe | 6 (15.4) | 3 (10.7) | 6 (54.5) | Â |
Skin toxicity | Â Mild | 15 (38.5) | 17 (60.7) | 5 (45.5) | 0.43 |
| Â | Â Severe | 0 | 1 (3.6) | 1 (9.1) | Â |
Endocrine toxicity | Â Mild | 5 (12.8) | 11 (39.2) | 4 (36.4) | 0.71 |
| Â | Â Severe | 0 | 1 (3.6) | 1 (9.1) | Â |
Required treatment termination | Â Yes | 4 (11) | 3 (11) | 6 (54) | 0.006 |
| Â | Â No | 33 (89) | 24 (89) | 5 (46) | Â |